Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Cell Mogrify
Cell Mogrify
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Mogrify appoints Dr Jane Osbourn as Chair of the Board
The OBE is also Chair of the Board of Directors of the BioIndustry Association, a Director of Babraham Bioscience Technologies, a Director of Cambridge Enterprise
Pharmaceutical
Mogrify appoints new CBO and COO
New executives at the biopharma company will be Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer
Research & Development
Cell Mogrify receives funding for regenerative cell therapy research
The funding from Innovate UK is designated to accelerate regenerative cell therapies, focusing on data-driven cell conversions
Recruitment
Cell Mogrify undergoes period of change
A cash injection and change in leadership gives momentum to the cell therapy company for direct cellular conversion platform
Subscribe now